HaemaLogiX Ltd’s Post

Regeneron touts success with bispecific antibody in multiple myeloma trial  Regeneron has released encouraging trial results for its multiple myeloma antibody, #linvoseltamab. The data from the Phase I/II LINKER-MM1 (NCT03761108) study was presented at the European Hematology Association (EHA) Congress 2024 in Madrid, Spain, on 13–16 June.  The 14-month follow up data demonstrated a 71% objective response rate, with 50% of patients achieving a complete response or better and 63% achieving a very good partial response or better, as determined by an independent review committee.  The median overall survival (OS) was 31 months, while the median progression free survival (PFS) and median duration of response (DoR) were not reached, as patients had not progressed yet. The median DoR for all responders was 29 months. https://lnkd.in/gsz5frwg

Dear Colleagues, Welcome to this Hematology Round Up from #ASCO24 . WE have focused on Hematologic malignancies with 3 presentations which were presented on June 2nd, 2024 The first presentation was the Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ) . Presented by Dr. Facon This trial presentation came with a concomitant publication on the New England Journal of Medicine (NEJM). https://lnkd.in/d2dRh6Hp The Second Presentation was the Phase 3 randomized BENEFIT study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). Presented by Dr. Leleu This trial presentation came with a concomitant publication on Nature Medicine https://lnkd.in/dSjVvk7X The final presentation was Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial. Presented by Dr Rodriguez-Otero Dr. Landgren discussed how quadruple therapies showed higher rates of minimal residual disease (MRD) and longer progression-free survival compared to triplets, regardless of age and transplant eligibility, potentially making them a new standard of care for newly diagnosed Multiple Myeloma. He emphasized the importance of minimal residual disease as an endpoint in newly diagnosed multiple myeloma, suggesting that having it as an early endpoint for accelerated approval could give patients faster access to new therapies. However, he also highlighted that bortezomib increases the rate of peripheral neuropathy. Dr. Landgren pointed out that CD38 monoclonal antibodies narrow the gap between transplant-eligible, younger, and fit patients, and transplant-ineligible, older, and less fit patients with multiple myeloma. Thank you for your attention and enjoy ASCO Disclosure: This Hematology Round Up was supported by Sanofi

TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease ➡ TREMFYA® is the first and only approved fully-human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23. ➡ TREMFYA® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis. It Seems that Janssen is betting high on Guselkumab, IL-23 inhibitor as it's started to get competition from biosimilar players for its blockbuster drug Ustekinumab (IL12/IL23) in Europe and in USA starting early next year.

Glenmark is proud to announce that our research paper on real-world clinical data on IV NEPA, a fixed dose combination of fosNEtupitant+ PAlonosetron, generated through phase IV study conducted on Indian patients was presented at the prestigious annual meeting of ASCO (American Society of Clinical Oncology) on 3rd June 2024, in Chicago, USA.  This first-of-its-kind research paper on IV NEPA was presented by Dr. Hanmant Barkate, Group Vice President and Global Head of Medical Affairs, on the clinical outcomes of the study titled ‘An open-label, single-arm, multicentre, prospective study to evaluate safety and effectiveness of IV NEPA - fixed dose combination of fosNEnetupitant-PAlonosetron in the prevention of CINV (chemotherapy-induced nausea and vomiting) in Indian patients (STOP-CINV study). The presentation was well received by Medical oncologists attending the ASCO 2024 annual meeting. This abstract is also published in the Journal of Clinical Oncology (JCO), a pubmed indexed, official journal of ASCO (https://lnkd.in/dx7RY749). Glenmark remains steadfast in its commitment to advancing research and improving patient outcomes in the therapeutic area of oncology. Our clinically value-added research work on IV NEPA, presented at ASCO, underscores our dedication to finding innovative solutions for better outcomes for patients with cancer and cancer-related complications.  #ASCO24 #CINV #SupportiveCancerCare #Glenmark #Innovation #IGI

After Muromonab-CD3 and Daclizumab, this week we will shine the spotlight on another antibody used to prevent kidney transplant rejection: Basiliximab (Simulect), approved in 1998. 🔬 Antibody type: Chimeric IgG1 💊 Brand name: Simulect 🏢 Company: Novartis 🎯 First indication: Prevention of acute kidney transplant rejection Basiliximab was a significant advancement in kidney transplant medicine. This monoclonal antibody targets the IL-2 receptor alpha chain (CD25) on activated T cells. By binding to CD25, Basiliximab inhibits IL-2 mediated T cell proliferation, which is a crucial process in the immune response leading to transplant rejection. Basiliximab's introduction has provided transplant patients with a safer and effective option to protect their new organs. Stay tuned for our next post, where we will explore more groundbreaking FDA-approved antibodies! #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #TransplantMedicine #KidneyTransplant #Biotechnology #MedicalInnovation

We are looking forward to #ACR24 in November where Capstan will debut key preclinical data on CPTX2309, our lead in vivo chimeric antigen receptor T cell (CAR-T) candidate.   Presentation details: - ORAL PRESENTATION: Effective Engineering of CD8+ T Cells from Autoimmune Disease Patients Utilizing a CD8-Targeted Lipid Nanoparticle Encoding an Anti-CD19 CAR mRNA (CPTX2309) - POSTER: Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR - POSTER: A Novel Product Candidate (CPTX2309) for In Vivo mRNA Engineering of Anti-CD19 CAR T Cells Utilizing Novel CD8-Targeted Lipid Nanoparticles More in today’s release: https://lnkd.in/esaXyhgF   American College of Rheumatology

Teaching our bodies to manufacture our own custom-reprogrammed immune cells inside the body (in vivo) is a **huge** deal. It rewrites the future of medicine. One reason it matters so much is that, as the wonderful Bruce Levine explained on my FutureBites podcast and when he and Tom Whitehead and Don Siegel walked me through the cell manufacturing facility at Penn Medicine, University of Pennsylvania Health System, customized cell manufacturing outside the body (in vitro) is a huge chunk of the cost of these cancer-busting CAR-T cell therapies. Our bodies make the best cell factories! And it’s not just CAR-T that changes, and it’s not just cancer therapies. Oh no, not by a long shot. We can use mRNA to teach our cells to self-manufacture all kinds of therapies. THIS is why I include in vivo cell manufacturing in every future of healthcare presentation I deliver. If you are interested in the future of healthcare, watch this. We are at the beginning of yet another revolution within a revolution. So many good things happening right now!!!!

Interesting and crucial to have more follow up... novel therapies are promising but we should be careful 

Remember the catchphrase from the #Ginsu knives commercial from the ‘80s: “But wait! There’s more!”? The pharmaceutical equivalent of Ginsu knives is the EpicentRx lead therapy, RRx-001 (nibrozetone), which is potentially active in a whole host of indications from cancer to endometriosis, oral mucositis, myocardial infarction, stroke, pulmonary hypertension, and neurodegenerative diseases. But wait! There’s more - so much more to read in this blog post here: https://bit.ly/45yklCS.

#ASH23 | 🎥 The Multiple Myeloma Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What are the latest updates on trispecific antibodies for the treatment of #MultipleMyeloma? Watch the full interview here: https://loom.ly/W9pTDbE #mmsm #myeloma